Literature DB >> 27650517

Sick leave and disability pension before and after diagnosis of multiple sclerosis.

Erik Landfeldt1, Anna Castelo-Branco2, Axel Svedbom2, Emil Löfroth3, Andrius Kavaliunas4, Jan Hillert4.   

Abstract

BACKGROUND: Multiple sclerosis (MS) is associated with considerable morbidity and serious disability, but little is known of the long-term impact of the disease on work ability.
OBJECTIVES: To assess sick leave (short-term absence) and disability pension (long-term absence) before and after diagnosis of MS.
METHODS: Patients with MS in Sweden were identified in a nationwide disease-specific register and matched with general population controls. Sick leave and disability pension were measured before and after index (i.e. the MS diagnosis date).
RESULTS: The final sample comprised 6092 patients and 60,345 controls (mean age 39 years; 70% female). The mean annual prevalence of sick leave ranged from 12% the first year after index to 23% after 11 years among patients and from 13% to 13% among controls. Corresponding estimates for disability pension were 12% and 55% for patients and 7% and 9% for controls. Significant differences in sick leave were observed up to 15 years before index and 3 years for disability pension.
CONCLUSION: Patients with MS in Sweden have elevated levels of sick leave and disability pension up to 15 years before disease diagnosis. Our results highlight the burden of disease on affected patients and society and underscore the substantial unmet medical need.
© The Author(s), 2016.

Entities:  

Keywords:  Multiple sclerosis; absenteeism; disability pension; longitudinal studies; sick leave; social insurance

Mesh:

Year:  2016        PMID: 27650517     DOI: 10.1177/1352458516667567

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  7 in total

1.  Importance of early treatment decisions on future income of multiple sclerosis patients.

Authors:  Andrius Kavaliunas; Ali Manouchehrinia; Hanna Gyllensten; Kristina Alexanderson; Jan Hillert
Journal:  Mult Scler J Exp Transl Clin       Date:  2020-10-07

2.  Trajectories of sickness absence and disability pension days among people with multiple sclerosis by type of occupation.

Authors:  Astrid R Bosma; Chantelle Murley; Jenny Aspling; Jan Hillert; Frederieke G Schaafsma; Johannes R Anema; Cécile R L Boot; Kristina Alexanderson; Alejandra Machado; Emilie Friberg
Journal:  Mult Scler       Date:  2021-10-06       Impact factor: 5.855

3.  Self-employment, sickness absence, and disability pension in multiple sclerosis.

Authors:  Alejandra Machado; Chantelle Murley; Jan Hillert; Kristina Alexanderson; Emilie Friberg
Journal:  Acta Neurol Scand       Date:  2022-07-04       Impact factor: 3.915

4.  Cost-of-Illness Progression Before and After Diagnosis of Multiple Sclerosis: A Nationwide Register-Based Cohort Study in Sweden of People Newly Diagnosed with Multiple Sclerosis and a Population-Based Matched Reference Group.

Authors:  Chantelle Murley; Petter Tinghög; Kristina Alexanderson; Jan Hillert; Emilie Friberg; Korinna Karampampa
Journal:  Pharmacoeconomics       Date:  2021-05-10       Impact factor: 4.981

5.  The long-term impact of early treatment of multiple sclerosis on the risk of disability pension.

Authors:  Erik Landfeldt; Anna Castelo-Branco; Axel Svedbom; Emil Löfroth; Andrius Kavaliunas; Jan Hillert
Journal:  J Neurol       Date:  2018-02-01       Impact factor: 4.849

6.  Trajectories of disposable income among people of working ages diagnosed with multiple sclerosis: a nationwide register-based cohort study in Sweden 7 years before to 4 years after diagnosis with a population-based reference group.

Authors:  Chantelle Murley; Olof Mogard; Michael Wiberg; Kristina Alexanderson; Korinna Karampampa; Emilie Friberg; Petter Tinghög
Journal:  BMJ Open       Date:  2018-05-09       Impact factor: 2.692

7.  Gender disparities in health resource utilization in patients with relapsing-remitting multiple sclerosis: a prospective longitudinal real-world study with more than 2000 patients.

Authors:  Dirk Schriefer; Nils-Henning Ness; Rocco Haase; Tjalf Ziemssen
Journal:  Ther Adv Neurol Disord       Date:  2020-10-24       Impact factor: 6.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.